Roy Rampling
Overview
Explore the profile of Roy Rampling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rampling R, Peoples S, Mulholland P, James A, Al-Salihi O, Twelves C, et al.
Clin Cancer Res
. 2016 May;
22(19):4776-4785.
PMID: 27225692
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a...
2.
Rooney A, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, et al.
Neuro Oncol
. 2013 Feb;
15(5):635-43.
PMID: 23444258
Background: Relatively little is known about the frequency, longitudinal course, independent associations, and reported causes of emotional distress in adults with primary cerebral glioma. We aimed to describe these features...
3.
Rooney A, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, et al.
J Neurooncol
. 2013 Feb;
113(1):49-55.
PMID: 23436131
When screening for depression in glioma patients, the utility of proxy carer report is unknown. We studied how patients and proxies differed in the frequency, severity and agreement of reported...
4.
Rooney A, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, et al.
Neuro Oncol
. 2012 Dec;
15(1):122-9.
PMID: 23229997
No depression screening tool is validated for use in cases of cerebral glioma. To address this, we studied the operating characteristics of the Hospital Anxiety and Depression Scale (Depression subscale)...
5.
Rampling R, Sanson M, Gorlia T, Lacombe D, Lai C, Gharib M, et al.
Neuro Oncol
. 2012 Feb;
14(3):344-50.
PMID: 22291006
We report a phase 1 study to examine the safety and recommended dose of the oral protein kinase C-beta inhibitor (anti-angiogenic) enzastaurin in combination with single-agent temozolomide. The study was...
6.
Rooney A, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, et al.
J Clin Oncol
. 2011 Oct;
29(32):4307-12.
PMID: 21990406
Purpose: There is a need for high-quality evidence regarding the frequency, independent clinical associations, and longitudinal course of depression in patients with cerebral glioma. Patients And Methods: This was a...
7.
Brada M, Stenning S, Gabe R, Thompson L, Levy D, Rampling R, et al.
J Clin Oncol
. 2010 Sep;
28(30):4601-8.
PMID: 20855843
Purpose: Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial...
8.
van den Bent M, Brandes A, Rampling R, Kouwenhoven M, Kros J, Carpentier A, et al.
J Clin Oncol
. 2009 Feb;
27(8):1268-74.
PMID: 19204207
Purpose: Approximately 50% of glioblastomas (GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In approximately 25% of instances, constitutively activated EGFR mutants...
9.
Raymond E, Brandes A, Dittrich C, Fumoleau P, Coudert B, Clement P, et al.
J Clin Oncol
. 2008 Oct;
26(28):4659-65.
PMID: 18824712
Purpose: To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas. Patients And Methods: This was a single-arm, phase II study. Eligible patients had recurrent glioma after...
10.
Albertella M, Loadman P, Jones P, Phillips R, Rampling R, Burnet N, et al.
Clin Cancer Res
. 2008 Feb;
14(4):1096-104.
PMID: 18281542
Purpose: AQ4N is a novel bioreductive prodrug under clinical investigation. Preclinical evidence shows that AQ4N penetrates deeply within tumors and undergoes selective activation to form AQ4, a potent topoisomerase II...